BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 20487712)

  • 1. [Chemotherapy-induced peripheral neuropathy: an unresolved issue].
    Velasco R; Bruna J
    Neurologia; 2010 Mar; 25(2):116-31. PubMed ID: 20487712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.
    Hausheer FH; Schilsky RL; Bain S; Berghorn EJ; Lieberman F
    Semin Oncol; 2006 Feb; 33(1):15-49. PubMed ID: 16473643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy-induced peripheral neuropathy].
    Noguchi E; Maeda Y
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1773-6. PubMed ID: 22083183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
    Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
    Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updating your peripheral neuropathy "know-how".
    Marrs J; Newton S
    Clin J Oncol Nurs; 2003; 7(3):299-303. PubMed ID: 12793336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.
    Cavaletti G; Frigeni B; Lanzani F; Mattavelli L; Susani E; Alberti P; Cortinovis D; Bidoli P
    Eur J Cancer; 2010 Feb; 46(3):479-94. PubMed ID: 20045310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
    Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
    Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
    Amara S
    Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.
    Argyriou AA; Bruna J; Marmiroli P; Cavaletti G
    Crit Rev Oncol Hematol; 2012 Apr; 82(1):51-77. PubMed ID: 21908200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence.
    Balayssac D; Ferrier J; Descoeur J; Ling B; Pezet D; Eschalier A; Authier N
    Expert Opin Drug Saf; 2011 May; 10(3):407-17. PubMed ID: 21210753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-induced neuropathy: A comprehensive survey.
    Miltenburg NC; Boogerd W
    Cancer Treat Rev; 2014 Aug; 40(7):872-82. PubMed ID: 24830939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge.
    Kandula T; Park SB; Cohn RJ; Krishnan AV; Farrar MA
    Cancer Treat Rev; 2016 Nov; 50():118-128. PubMed ID: 27664395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.
    Kuroi K; Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Watanabe T; Bain S; Hausheer FH
    Jpn J Clin Oncol; 2008 Nov; 38(11):748-54. PubMed ID: 18845520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced peripheral neuropathy: prevention and treatment.
    Pachman DR; Barton DL; Watson JC; Loprinzi CL
    Clin Pharmacol Ther; 2011 Sep; 90(3):377-87. PubMed ID: 21814197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool.
    Tofthagen CS; McMillan SC; Kip KE
    Cancer Nurs; 2011; 34(4):E10-20. PubMed ID: 21242773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents.
    Argyriou AA; Zolota V; Kyriakopoulou O; Kalofonos HP
    J BUON; 2010; 15(3):435-46. PubMed ID: 20941808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.
    Cavaletti G; Frigeni B; Lanzani F; Piatti M; Rota S; Briani C; Zara G; Plasmati R; Pastorelli F; Caraceni A; Pace A; Manicone M; Lissoni A; Colombo N; Bianchi G; Zanna C;
    J Peripher Nerv Syst; 2007 Sep; 12(3):210-5. PubMed ID: 17868248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of chemotherapy-induced peripheral neuropathy.
    Kaley TJ; Deangelis LM
    Br J Haematol; 2009 Apr; 145(1):3-14. PubMed ID: 19170681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice.
    Wickham R
    Clin J Oncol Nurs; 2007 Jun; 11(3):361-76. PubMed ID: 17623621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.